Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603924 · ClinicalTrials.gov registry record · Phase 2
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
A Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT04603924 is a Phase 2 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT04603924, a Phase 2 study, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
Study of ANA001 in Moderate and Severe COVID-19 Patients
Interventions
- DRUG Placebo
- DRUG Niclosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603924
The ClinicalTrials.gov registry entry for NCT04603924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04603924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04603924 about?
NCT04603924 is a clinical study titled "Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients". Study of ANA001 in Moderate and Severe COVID-19 Patients
What is the current status of trial NCT04603924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2020-10-07. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT04603924?
The interventions under investigation include: Placebo (DRUG), Niclosamide (DRUG).
Who is sponsoring clinical trial NCT04603924?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.